Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 8, 2012, Pages 1074-1083

  Choi, Min Koo ^a   Song, Im Sook ^b,c  

^a Dankook University   (South Korea)

^b Inje University   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

BCRP; Intestinal absorption; MRP2; P gp; PDE5 inhibitors

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; SILDENAFIL; VARDENAFIL; VERLUKAST;

ARTICLE; CELL CULTURE; CELL STRAIN; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TRANSPORT; INHIBITION KINETICS; PROTEIN EXPRESSION;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; HUMANS; IMIDAZOLES; INTESTINAL ABSORPTION; LEUKOTRIENE ANTAGONISTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROPIONATES; PURINES; QUINOLINES; SULFONES; TRIAZINES;

EID: 84863716828     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01498.x     Document Type: Article

References (29)

1. Klotz T, et al,. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 1: 32-39. (Pubitemid 33777030)
2. Rajagopalan P, et al,. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 3: 260-267. (Pubitemid 36232654)
3. Leslie EM, et al,. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 3: 216-237. (Pubitemid 40552845)
4. Borst P, et al,. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 16: 1295-1302. (Pubitemid 30662093)
5. Rappa G, et al,. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout models. Biochem Pharmacol 1999; 4: 557-562. (Pubitemid 29298179)
6. Lorico A, et al,. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 1997; 23: 5238-5242. (Pubitemid 27516355)
7. Ortiz DF, et al,. MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte. Am J Physiol 1999; 6 (Pt 1): G1493-G1500. (Pubitemid 29323456)
8. Hirohashi T, et al,. Hepatic expression of multidrug resistance- associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol 1998; 6: 1068-1075. (Pubitemid 28280450)
9. Toyoda Y, et al,. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica 2008; 7-8: 833-862.
10. Chen ZS, et al,. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 2002; 11: 3144-3150.
11. Reid G, et al,. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003; 5: 1094-1103. (Pubitemid 36529928)
12. Jedlitschky G, et al,. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 39: 30069-30074.
13. Chen ZS, et al,. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 2003; 2: 351-358.
14. Shi Z, et al,. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011; 8: 3029-3041.
15. Ding PR, et al,. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS ONE 2011; 4: e19329.
16. Ahn HJ, et al,. In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223. Xenobiotica 2011; 6: 445-455.
17. Silbermann MH, et al,. Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance. Int J Cancer 1989; 4: 722-726. (Pubitemid 19258751)
18. Horikawa M, et al,. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 2002; 1: 23-33.
19. Konig J, et al,. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999; 2: 377-394.
20. Rabindran SK, et al,. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998; 24: 5850-5858. (Pubitemid 29006428)
21. Troutman MD, Thakker DR,. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 2003; 8: 1210-1224. (Pubitemid 36951846)
22. Thiel-Demby VE, et al,. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Mol Pharm 2009; 1: 11-18.
23. Mehrotra N, et al,. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 3: 253-264. (Pubitemid 46701452)
24. Ku HY, et al,. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 2008; 6: 986-990.
25. Watkins PB, et al,. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 4: 1029-1036. (Pubitemid 18075638)
26. de Waziers I, et al,. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 1: 387-394. (Pubitemid 20141526)
27. Paine MF, et al,. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 3: 1552-1562. (Pubitemid 28016533)
28. Wu CY, et al,. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 5: 492-497.
29. Hebert MF, et al,. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 5: 453-457.